Results 201 to 210 of about 1,652,070 (380)
We are investigating the magnetic characteristics of pre-main sequence Herbig Ae/Be stars, with the aim of (1) understanding the origin and evolution of magnetism in intermediate-mass stars, and (2) exploring the influence of magnetic fields on accretion,
Alecian, E.+12 more
core +1 more source
This study highlights the importance of multi‐omic analyses in characterizing colorectal cancers. Indeed, our analysis revealed a rare CMS1 exhibiting dampened immune activation, including reduced PD‐1 expression, moderate CD8+ T‐cell infiltration, and suppressed JAK/STAT pathway.
Livia Concetti+10 more
wiley +1 more source
Daylight Photography of Stars as a means of testing the Equivalence Postulate in the Theory of Relativity [PDF]
A. F. Lindemann, F. A. Lindemann
openalex +1 more source
Dual targeting of AKT and mTOR using MK2206 and RAD001 reduces tumor burden in an intracardiac colon cancer circulating tumor cell xenotransplantation model. Analysis of AKT isoform‐specific knockdowns in CTC‐MCC‐41 reveals differentially regulated proteins and phospho‐proteins by liquid chromatography coupled mass spectrometry. Circulating tumor cells
Daniel J. Smit+19 more
wiley +1 more source
Spectroscopic Observations of the Motion of Stars in the line of Sight, made at the Temple Observatory, Rugby [PDF]
G. M. Seabroke
openalex +1 more source
Inhibitor of DNA binding‐1 is a key regulator of cancer cell vasculogenic mimicry
Elevated expression of transcriptional regulator inhibitor of DNA binding 1 (ID1) promoted cancer cell‐mediated vasculogenic mimicry (VM) through regulation of pro‐angiogenic and pro‐cancerous genes (e.g. VE‐cadherin (CDH5), TIE2, MMP9, DKK1). Higher ID1 expression also increased metastases to the lung and the liver.
Emma J. Thompson+11 more
wiley +1 more source
XIX. On the parallax of the fixed stars [PDF]
John Frederick William Herschel
openalex +1 more source
Alectinib resistance in ALK+ NSCLC depends on treatment sequence and EML4‐ALK variants. Variant 1 exhibited off‐target resistance after first‐line treatment, while variant 3 and later lines favored on‐target mutations. Early resistance involved off‐target alterations, like MET and NF2, while on‐target mutations emerged with prolonged therapy.
Jie Hu+11 more
wiley +1 more source